Imprivata Bolsters NHS Access Management with Passwordless Authentication

  • Imprivata released new features for its Enterprise Access Management (EAM) platform on March 17, 2026.
  • The update focuses on advanced access management and passwordless authentication tailored for UK healthcare providers, specifically addressing compliance requirements like the Cyber Assessment Framework (CAF)-aligned Data Security and Protection Toolkit (DSPT) and NHS England Spine Authentication.
  • New features include context-aware passwordless authentication, AI-powered behavioral analytics, and role-based access controls.
  • Imprivata will demonstrate the new functionality at Digital Health Rewired 2026 in Birmingham on March 24-25.

The UK’s National Health Service (NHS) is facing mounting pressure to modernize its IT infrastructure while adhering to increasingly complex cybersecurity and compliance mandates. Imprivata’s move to integrate advanced access management and passwordless authentication directly addresses this need, positioning the company to capitalize on a growing market for secure and efficient healthcare technology solutions. This expansion is likely a response to broader trends of Zero Trust architecture adoption and the increasing prevalence of remote work within the NHS.

Regulatory Headwinds
The success of Imprivata’s offering hinges on its ability to navigate the evolving and increasingly stringent regulatory landscape within the UK healthcare sector, particularly the DSPT and Spine Authentication requirements.
Adoption Rate
The pace at which NHS Trusts and providers adopt the new passwordless authentication features will be a key indicator of Imprivata’s ability to reduce workflow friction and demonstrate tangible value to its clients.
Competitive Dynamics
How competitors respond to Imprivata’s enhanced EAM platform, particularly in offering similar CAF-aligned and Spine Authentication support, will determine the long-term market share and pricing pressures within the UK healthcare access management space.